P. Anagnostis Et Al. , "Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al.," MATURITAS , vol.102, pp.76-77, 2017
Anagnostis, P. Et Al. 2017. Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al.. MATURITAS , vol.102 , 76-77.
Anagnostis, P., Paschou, S. A., Mintziori, G., Ceausu, I., Depypere, H., Lambrinoudaki, I., ... Mueck, A.(2017). Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al.. MATURITAS , vol.102, 76-77.
Anagnostis, Panagiotis Et Al. "Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al.," MATURITAS , vol.102, 76-77, 2017
Anagnostis, Panagiotis Et Al. "Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al.." MATURITAS , vol.102, pp.76-77, 2017
Anagnostis, P. Et Al. (2017) . "Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al.." MATURITAS , vol.102, pp.76-77.
@article{article, author={Panagiotis Anagnostis Et Al. }, title={Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al.}, journal={MATURITAS}, year=2017, pages={76-77} }